Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
Open Access
- 1 October 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (19) , 7178s-7186s
Abstract
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequential high-dose treatments of radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell carcinoma. Here, we report the dosimetric analysis and the relationship between the development of a human antichimeric antibody response and altered pharmacokinetics. Experimental Design: Patients (n = 29) with progressive metastatic renal cell carcinoma received a low dose (222 MBq) of [131I]cG250 for dosimetric analysis, followed by the first radioimmunotherapy with 2,220 MBq/m2 [131I]cG250 (n = 27) 1 week later. If no grade 4 hematologic toxicity was observed, a second low dose of [131I]cG250 (n = 20) was given 3 months later. Provided that no accelerated blood clearance was observed, a second radioimmunotherapy of [131I]cG250 was administered at an activity-dose level of 1,110 MBq/m2 (n = 3) or 1,665 MBq/m2 (n = 16). After each administration, whole-body images were obtained and the pharmacokinetics and the development of human antichimeric antibody responses were determined. Radiation-absorbed doses were calculated for whole body, red marrow, organs, and metastases. Results: No correlation was found between hematologic toxicity and radiation-absorbed dose to the whole body or bone marrow, nor administered activity (MBq and MBq/kg). The tumor-absorbed doses varied largely. An inverse relation between tumor size and radiation-absorbed dose was found. Most tumor lesions received Conclusions: Dosimetric analysis did not adequately predict the degree of bone marrow toxicity. When human antichimeric antibody developed, the rapid clearance of radioactivity from the blood and body prohibited further treatment. According to the calculated absorbed dose in metastatic lesions, future radioimmunotherapy studies with radiolabeled cG250 should aim at treatment of small-volume disease or treatment in an adjuvant setting.Keywords
This publication has 27 references indexed in Scilit:
- Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Comparison of Methods for Predicting Myelotoxicity for Non-Marrow Targeting I-131-Antibody TherapyCancer Biotherapy and Radiopharmaceuticals, 2003
- Hematologic Toxicity in Radioimmunotherapy: Dose-Response Relationships for I-131 Labeled Antibody TherapyCancer Biotherapy and Radiopharmaceuticals, 2002
- Radioimmunotherapy of small-volume disease of metastatic colorectal cancerCancer, 2002
- Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapyCancer, 2002
- Tumor-Absorbed-Dose Estimates versus Response in Tositumomab Therapy of Previously Untreated Patients with Follicular non-Hodgkin's Lymphoma: Preliminary ReportCancer Biotherapy and Radiopharmaceuticals, 2000
- HumanMN/CA9Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain RelationshipsGenomics, 1996
- Renal cell carcinomaCurrent Opinion in Oncology, 1996
- Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250International Journal of Cancer, 1994
- Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma-Associated AntigensInternational Journal of Gynecological Pathology, 1991